How HIV Prevention Drugs Work: From Pills to Injections
PrEP medications have transformed HIV prevention from near-certain infection to near-zero risk. Here's how these drugs block the virus—and why a new twice-yearly injection is changing the game.
A Medical Breakthrough That Reshaped HIV Prevention
For decades, preventing HIV relied almost entirely on behavioral measures: condoms, clean needles, and avoiding high-risk exposure. Then came a class of drugs that changed the equation entirely. Pre-exposure prophylaxis—known as PrEP—gives HIV-negative people a pharmaceutical shield against the virus. Taken correctly, modern PrEP drugs reduce the risk of acquiring HIV through sex by approximately 99%, according to the U.S. Centers for Disease Control and Prevention (CDC).
Understanding how these drugs work—and how the newest generation leapfrogs the daily pill—reveals a remarkable story of molecular biology and medical ingenuity.
The HIV Lifecycle: What PrEP Must Stop
HIV is a retrovirus. When it enters the body, it targets CD4 T-cells—white blood cells that form the backbone of the immune system. The virus injects its genetic material (RNA) into these cells and hijacks their machinery to replicate. Left unchecked, this destroys the immune system, eventually leading to AIDS.
PrEP drugs are designed to interrupt this lifecycle before the virus can establish a permanent foothold. The key is maintaining enough of the drug in the bloodstream and inside cells so that any HIV encountered after exposure is stopped cold—before it can integrate into the host's DNA.
How Daily Oral PrEP Works
The first FDA-approved PrEP medication, Truvada (approved 2012), combines two antiretroviral drugs: emtricitabine and tenofovir disoproxil fumarate. A second option, Descovy (approved 2019), uses emtricitabine paired with a refined formulation called tenofovir alafenamide, which reaches cells more efficiently and causes less kidney and bone stress.
Both drugs belong to a class called nucleoside reverse transcriptase inhibitors (NRTIs). HIV depends on an enzyme called reverse transcriptase to convert its RNA into DNA—a prerequisite for integrating into a cell's genome. NRTIs mimic the building blocks that reverse transcriptase uses, effectively jamming the enzyme. Without functional reverse transcriptase, HIV cannot replicate.
The catch: the drugs must be taken every day to maintain protective levels in the bloodstream. Studies show that skipping doses significantly reduces protection, and adherence remains the chief challenge for daily PrEP programs worldwide, according to HIV.gov.
Injectable PrEP: A Long-Acting Alternative
The adherence problem drove researchers to develop long-acting alternatives. Apretude (cabotegravir), an injectable PrEP approved in 2021, requires only six injections per year. It works differently from oral PrEP, blocking a different enzyme called integrase, which HIV needs to splice its DNA into a host cell's chromosomes.
But the most significant advance came with lenacapavir, sold as Yeztugo, which the FDA approved in 2025 and the World Health Organization recommended for HIV prevention shortly after. Lenacapavir requires only two injections per year—a once-every-six-months shot.
Lenacapavir: A First-in-Class Mechanism
Lenacapavir is the world's first capsid inhibitor—a drug targeting a completely different viral structure than any previous HIV medication. The HIV capsid is a cone-shaped protein shell that protects the virus's genetic cargo and enzymes during replication. Lenacapavir binds at the junction between neighboring capsid protein subunits, disrupting multiple stages of the viral lifecycle simultaneously: it blocks the capsid from entering the cell nucleus, prevents viral DNA from integrating, and stops new virus particles from assembling properly.
This multi-stage attack makes it exceptionally potent. In the landmark PURPOSE 1 and PURPOSE 2 clinical trials, involving thousands of participants across multiple continents, lenacapavir reduced HIV acquisition risk by 96–100%. In PURPOSE 1, not a single participant in the lenacapavir group contracted HIV, according to The New England Journal of Medicine.
Who Should Take PrEP?
The CDC recommends PrEP for HIV-negative individuals who are at substantial risk of infection, including people with an HIV-positive partner, people who do not consistently use condoms with partners of unknown HIV status, and people who inject drugs and share equipment. A doctor will screen for kidney function, hepatitis B, and other factors before prescribing. PrEP does not protect against other sexually transmitted infections—condoms still play an important complementary role.
The Road Ahead
PrEP has become one of modern medicine's most powerful HIV-prevention tools. Daily oral pills, six-injection-per-year cabotegravir, and now twice-yearly lenacapavir represent three generations of innovation—each reducing the burden of adherence while maintaining or exceeding earlier levels of protection. With WHO endorsement opening the door to wider access in low- and middle-income countries, the once-distant goal of ending the HIV epidemic is looking measurably closer.
